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INTRODUCTION
Myasthenia gravis (MG) is an autoimmune disorder that affects 
neuromuscular transmission as a result of antibodies binding 
to elements of the neuromuscular junction, most commonly 
the acetylcholine receptor (AChR).1,2 The prevalence of MG is 
increasing in South Korea3,4 and many patients suffer from 
uncontrolled symptoms. In recent years, the prognosis for pa-
tients with MG has generally been good. One major reason for 
this improved prognosis is the increasing availability of im-
munomodulating drugs.5
Tacrolimus is a calcineurin inhibitor and inhibits T cell acti-
vation.6-8 It was originally used to prevent rejection after organ 
transplantation. Since successful treatment of MG with tacroli-
mus was reported in 2002,9 it has been used to treat MG. Be-
cause MG is a lifelong medical condition, tacrolimus, like other 
immunomodulating drugs, should be used as part of a long-term 
plan. Although a number of studies have assessed tacrolimus 
use in MG,10-22 the long-term safety and efficacy of tacrolimus 
in MG is not entirely understood.21 In addition, most observa-
tional studies have investigated the efficacy of tacrolimus by 
comparing steroid doses and clinical severity at the start of tacro-
limus administration with those after treatment. However, this 
comparison is not appropriate because MG has a fluctuating 
clinical course and the addition of immunosuppressants like 
tacrolimus may be made during clinical deterioration and may 
accompanied by an increase in steroid doses. Although two 
previous studies investigated clinical status and steroid doses 4 
weeks before the start of tacrolimus, the small number of pa-
tients included (19 and 9 patients) was too few for generaliza-
tion and the four-week period may be insufficient given the 
long clinical course of MG.10,17
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The purpose of this study was to investigate the long-term 
safety and efficacy of tacrolimus in the treatment of MG by 
analyzing clinical status and steroid doses before and after ta-
crolimus treatment in real-world clinical practice.
MATERIALS AND METHODS
This was a retrospective study including all patients diagnosed 
with MG and treated with tacrolimus from December 2005 to 
July 2015 at Severance Hospital, Yonsei University Health System. 
The requirement to obtain informed consent from study sub-
jects was waived by the Institutional Review Board (IRB) of Sev-
erance Hospital, Yonsei University College of Medicine, Seoul, 
Korea (IRB No.: 4-2015-0322).
A diagnosis of MG was based on the signs and symptoms of 
muscle fatigue with at least one of the following: 1) 10% or more 
decrease in compound muscle action potential in response to 
low-frequency supramaximal repetitive nerve stimulation with 
five stimuli in a train, 2) positive serum antibodies against 
AChR or muscle-specific tyrosine kinase (MuSK), or 3) im-
provement in muscle fatigue after an intramuscular injection 
of neostigmine. Generally, the initiating dose of tacrolimus was 
3 mg once daily. If the effects were insufficient, dosage was in-
creased to reach a trough level between 7–10 ng/dL. If the pa-
tient complained of adverse events, the dose was decreased. 
Immunosuppressive drugs other than prednisolone were not 
used in combination with tacrolimus.
In total, 160 MG patients were identified. Medical records 
were reviewed to collect information on age, sex, age at symp-
tom onset, tacrolimus administration and discontinuation, 
thymus histopathology, Myasthenia Gravis Foundation of 
America (MGFA) clinical classification, MGFA post-intervention 
status (PIS),23 myasthenic functional score (MFS),24 and MG 
treatment, including corticosteroids, immunosuppressants, 
pyridostigmine, and thymectomy.
MFS is an indicator of MG severity and was first used in a tri-
al comparing azathioprine to prednisolone.24 It is a five-grade 
functional scale, defined as 1) complete remission; 2) minor 
symptoms allowing normal activity, except for exertional ac-
tivity; 3) moderate symptoms allowing occupational or partial 
daily activity; 4) major disability requiring discontinuation of 
occupational activity or major reduction of daily activity; and 
5) major disability requiring continuous help from others or 
mechanical ventilation.24
Safety
Symptoms, medical co-morbidities, and laboratory analyses, 
such as blood urea nitrogen (BUN), creatinine (Cr), aspartate 
transaminase, alanine transaminase, phosphate, magnesium, 
sodium, potassium, chloride, lipid profile, fasting glucose, 
erythrocyte sedimentation rate, and C-reactive protein, were 
routinely monitored, and the results were collected from medi-
cal records. Experienced neurologists reviewed adverse effects 
with laboratory tests for all patients, including tests for com-
plete blood count, serum chemistry, and electrolytes.
Efficacy
To evaluate the efficacy of tacrolimus, MGFA clinical classifica-
tion, MGFA PIS, MFS, and dose of oral prednisolone were eval-
uated. Data were analyzed at the initiation of tacrolimus treat-
ment and at 6, 12, 18, and 24 months before and after treatment 
initiation. In patients who were treated with tacrolimus for 
more than 24 months, data were also retrieved from the last 
visit when tacrolimus was prescribed. 
Statistics
Oral prednisolone doses were compared at different time 
points. A linear, mixed, repeated measures covariance model 
with unstructured covariance was used. Additionally, post hoc 
analyses were performed to compare prednisolone doses at 
each time point. We used Bonferroni correction for the multi-
ple outcomes. Statistical analyses were performed using IBM 
SPSS Statistics for Windows, version 23 (IBM Corp., Armonk, 
NY, USA). 
RESULTS
Demographic characteristics
Patient demographic characteristics are summarized in Table 
1. A total of 160 MG patients (124 females, 36 males) were 
identified. Females were more likely to be started on tacroli-
mus than males, mainly owing to their intolerance of hirsut-
ism and gingival hyperplasia caused by the previous immu-
nosuppressant (cyclosporine). The mean duration of MG at 
tacrolimus initiation was 10.8±8.4 years. Anti-AChR antibody 
was detected in 140 (87.5%) patients, and anti-MuSK antibody 
was positive in seven (4.4%) patients. Thymectomy was per-
formed in 87 (54.4%) of the 160 patients. Thymoma was asso-
ciated in 40 patients. At tacrolimus treatment initiation, MG 
severity according to MGFA clinical classification was mild 
(MGFA I or II) in 95 patients and more severe (MGFA III or IV) 
in 58 patients. Seven patients were free of MG symptoms and 
started tacrolimus due to steroid side effects (4), cyclosporine 
side effects (2), and steroid tapering failure (1) at the initiation 
of tacrolimus treatment (Table 1).
Treatment with tacrolimus
The mean duration of treatment with tacrolimus was 16.48± 
17.93 months (range 0–71 months). The median tacrolimus 
dose was 3.3±0.8 mg. In 52 patients who had been treated with 
prednisolone with or without pyridostigmine bromide, tacroli-
mus was added to prednisolone. In 99 patients who had been 
treated with prednisolone and immunosuppressants with or 
without pyridostigmine bromide, tacrolimus replaced the pre-
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vious immunosuppressants. In nine patients who had been 
treated with immunosuppressants with or without pyridostig-
mine bromide, tacrolimus replaced the previous immunosup-
pressant. Among 108 patients who were using immunosup-
pressants other than tacrolimus, 50 changed to tacrolimus due 
to adverse effects from the previous immunosuppressant. The 
previous immunosuppressant therapies other than predniso-
lone are listed in Table 1. In 105 (65.6%) of the 160 patients, ta-
crolimus was started during an exacerbation of MG.
Safety 
Adverse events that were possibly associated with tacrolimus 
are presented in Table 2. Adverse events were observed in 68 
patients (42.5%). The more frequent adverse events were hy-
percholesterolemia, diarrhea, BUN/Cr elevation, hair loss, 
and hyperglycemia. BUN/Cr elevation was mild and resolved 
spontaneously or after the tacrolimus dose was adjusted in 27 
of 28 patients. In one patient, BUN/Cr elevation resolved only 
after tacrolimus was discontinued. Most adverse events were 
not serious and were well-managed by adjusting tacrolimus 
dosage, treating the symptoms, or both. However, tacrolimus 
was discontinued due to adverse events in 23 (14.4%) patients 
(Fig. 1). The most frequent adverse event that led to discontin-
uation were diarrhea (n=13) and hair loss (n=3). Among the 
23 patients who discontinued tacrolimus due to adverse 
events, 17 discontinued within the first year. All adverse 
events that led to discontinuation resolved after the discontin-
uation. In addition, 13 patients stopped tacrolimus because of 
ineffectiveness (n=9), pregnancy plan (n=2), or patient refusal 
to continue (n=2). One hundred and twenty-four people were 
continuously on tacrolimus, although the maintenance peri-
od differed among them.
Efficacy
Time courses of MGFA clinical classification, MGFA PIS, and 
Table 1. Demographic Features of 160 MG Patients
Characteristic Result
Age at onset (yr) 31.9±15.7 
Sex (male/female) 36 (22.5)/124 (77.5)
Age at tacrolimus administration (yr) 43.2±13.8 
Duration of MG at tacrolimus administration (yr) 10.8±8.4 
Thymectomized patients 87 (54.4): normal thymus 12, hyperplasia 30, thymoma 40, involution 2, unknown 3
Anti-AChR antibody 140 (87.5)
Anti-MuSK antibody (seropositive/borderline) 7 (4.4)/2 (1.3)
MGFA at tacrolimus administration (n) I (39), IIa (26), IIb (30), IIIa (27), IIIb (16), IVa (8), IVb (7), V (0), symptom free (7)
Duration of tacrolimus therapy (month) 16.48±17.93 (range 0–71)
Dose of tacrolimus (mg) 3.3±0.8 (range 2–8)
Long-term immunotherapy before tacrolimus treatment (n)
Azathioprine (3), azathioprine+prednisolone (34), cyclosporine (6), cyclosporine+prednisolone (58), 
azathioprine+cyclosporine+prednisolone (4), mycophenolate mofetil+prednisolone (3), 
prednisolone (52)
MG, myasthenia gravis; AChR, acetylcholine receptor; MuSK, muscle-specific tyrosine kinase; MGFA, Myasthenia Gravis Foundation of America.
Variable are presented as mean±SD or number (percentage) unless otherwise noticed.
Table 2. Adverse Events of Tacrolimus
Adverse event* n (%)
Hypercholesterolemia   36 (19.5)
Diarrhea   30 (16.2)
BUN/Cr elevation   28 (15.1)
Hair loss 12 (6.5)
Hyperglycemia 10 (5.4)
Hyperphosphatemia   8 (4.3)
Hypophosphatemia   8 (4.3)
Iron deficiency anemia   7 (3.8)
Abdominal discomfort  7 (3.8)
Tremor   5 (2.7)
Paresthesia   4 (2.2)
Eczema   3 (1.6)
Headache   3 (1.6)
High blood pressure   3 (1.6)
Muscle cramp   3 (1.6)
Thrombocytopenia   3 (1.6)
Tinea pedis, oral fungal infection   2 (1.1)
Chills   2 (1.1)
Hyperkalemia   2 (1.1)
Hypokalemia   2 (1.1)
Dizziness   1 (0.5)
Myalgia   1 (0.5)
Visual disturbances   1 (0.5)
Dysmenorrhea   1 (0.5)
Oral ulcer   1 (0.5)
Nail cracks   1 (0.5)
Lower extremity edema   1 (0.5)
Total number of adverse events observed   185 (100.0)
Number of patients with adverse events 68/160 (42.5)
BUN/Cr, blood urea nitrogen/creatinine.
*Adverse events of tacrolimus were either reported by patients or detected in 
laboratory results. Multiple adverse events occurred concurrently in some pa-
tients.
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MFS are illustrated in Fig. 2. The follow-up duration of MG be-
fore initiating tacrolimus was more than 6 months in 154, 12 
months in 144, 18 months in 136, and 24 months in 127 pa-
tients. The duration of tacrolimus treatment was more than 6 
months in 121, 12 months in 70, 18 months in 53, and 24 months 
in 29 patients.
The proportion of patients with MGFA clinical classification 
I or II was 59.4% at the initiation of tacrolimus and increased to 
96.6% at the final visit. The proportion of patients with MGFA 
PIS complete stable remission (CSR), pharmacologic remis-
sion (PR), or minimal manifestation (MM) was 25% at the initi-
ation of tacrolimus and increased to 96.6% at the final visit. The 
proportion of patients with MFS 1 or 2 was 60% at the initiation 
of tacrolimus and increased to 96.6% at the final visit. Mean ta-
crolimus maintenance period was 14.3 months at the final visit.
The mean prednisolone dose±standard error was 15.2±1.1 
mg/day at 24 months, 14.2±1.0 mg/day at 18 months, 13.5±0.8 
mg/day at 12 months, and 14.6±0.9 mg/day at 6 months before 
initiating tacrolimus. The mean dose of prednisolone was 
21.2±1.2 mg/day at the initiation of tacrolimus. The mean pred-
nisolone dose was 14.2±0.7 mg/day at 6 months, 11.8±0.6 mg/
day at 12 months, 11.3±0.8 mg/day at 18 months, and 10.9± 0.7 
mg/day at 24 months after initiating tacrolimus. Compared to 
the baseline, prednisolone dose was significantly lower at 6, 
12, 18, and 24 months of using tacrolimus [6.95±0.89 mg/day, 
95% confidence interval (CI) 5.18 to 8.71; 9.42±0.99 mg/day, 
95% CI 7.46 to 11.38; 9.93±1.18 mg/day, 95% CI 7.59 to 12.27; 
and 10.28±1.08 mg/day, 95% CI 8.14 to 12.42; respectively, p< 
0.001]. Prednisolone dose at 6 months prior to tacrolimus and 
6 months after tacrolimus did not differ significantly (0.38± 
1.03 mg/day, 95% CI 1.66 to 2.42; p=0.716). However, prednis-
olone doses decreased significantly from 6 months before ini-
tiating tacrolimus to 12 months after (2.85±0.92 mg/day, 95% 
CI 1.03 to 4.66; p=0.002), 18 months after (3.36±0.99 mg/day, 
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Fig. 1. Adverse effects leading to cessation of tacrolimus according to the 
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95% CI 1.40 to 5.32; p=0.001), and 24 months after (3.71±0.93 
mg/day, 95% CI 1.86 to 5.56; p<0.001) (Fig. 3).
DISCUSSION
In this study, we reported data from 160 MG patients treated 
with tacrolimus for a mean period of 16.48 months (range 0–71 
months). The mean duration from MG onset to the start of ta-
crolimus treatment was about 11 years. A total of 108 patients 
(67.5%) had been administered other immunosuppressants, 
such as azathioprine, cyclosporine, and mycophenolate mofetil, 
which were replaced with tacrolimus. These subjects experi-
enced repeated worsening of MG or difficulty in reducing the 
prednisolone dose. Therefore, most subjects in this study had 
a long and intractable disease course and were resistant to or 
dependent on prednisolone. In 105 patients (65.6%), tacroli-
mus was used due to exacerbation of MG, which also required 
an increase in the prednisolone dose administered. Therefore, 
MG severity and prednisolone dose at the time of tacrolimus 
initiation cannot be compared with those after tacrolimus 
treatment, as has been done in most previous studies on ta-
crolimus in MG9,11-16,18 because an increase in prednisolone 
can influence the course of MG. In addition, the efficacy of ta-
crolimus can be overestimated by regression toward the mean. 
Therefore, we investigated MG severity and prednisolone 
dose for two years before and after initiating tacrolimus ad-
ministration.
To evaluate the efficacy of tacrolimus, MGFA clinical classifi-
cation, MGFA PIS, MFS, and oral prednisolone dose were in-
vestigated. None of the four parameters changed significantly 
over the two years before tacrolimus administration. At the 
time of tacrolimus administration, however, the proportion of 
patients with severe MG status and the oral prednisolone dose 
both increased. As the duration of tacrolimus use increased, 
the proportion of patients with severe MG status decreased. 
At two years after tacrolimus initiation, the proportions of pa-
tients with CSR, PR, or MM were significantly higher than those 
observed at the initiation of tacrolimus and before tacrolimus 
use. The oral prednisolone dose also decreased as the duration 
of tacrolimus use increased. The mean oral prednisolone dose 
was 14.6±0.9 mg/day at 6 months before the initiation of tacro-
limus, 21.2±1.2 mg/day at the initiation of tacrolimus, 14.2±0.7 
mg/day at 6 months after tacrolimus treatment, and 11.8±0.6 
mg/day at 12 months after tacrolimus treatment. At 6 months 
after tacrolimus treatment, the oral prednisolone dose was sig-
nificantly lower than that at the initiation of tacrolimus. How-
ever, the doses between 6 months before (14.6±0.9 mg/day) 
and after (14.2±0.7 mg/day) the initiation of tacrolimus did not 
differ significantly. The oral prednisolone dose at 12 months af-
ter tacrolimus treatment was significantly lower than that at 6 
months before initiating tacrolimus and at the initiation of ta-
crolimus. These findings suggest that long-term treatment with 
tacrolimus may improve the clinical status and decrease the re-
quired dose of oral prednisolone in patients with MG. Consid-
ering that our MG patients had a long and intractable disease 
courses, the steroid-sparing effect of long-term tacrolimus ther-
apy shown in this study is encouraging.
Most adverse events of tacrolimus in this study were not se-
rious, similar to the results of previous studies.9-21 If necessary, 
tacrolimus was reduced or discontinued, and the adverse 
events resolved. In our study, 42.5% of patients had an adverse 
event (Table 2). In previous reports, the proportion of patients 
with adverse events varied from 0% to 87.5%.9-21 This variation 
in incidence of adverse events may be a result of different study 
designs. In a randomized, double-blind, placebo-controlled 
study of tacrolimus, 87.5% of patients treated with tacrolimus 
had adverse events.19 However, the rate of adverse events was 
low in most retrospective studies.9-18 These results suggest that 
adverse events of tacrolimus rely on patient reports without 
systemic investigation in many retrospective studies. In this 
study, any adverse events that were possibly associated with 
tacrolimus were included, and the causal relationship between 
tacrolimus and adverse events was not considered. Long-term 
use of other medications, including prednisolone, other immu-
nosuppressants, and pyridostigmine bromide, may have af-
fected the rate of adverse events in this study. Although most 
adverse events were not serious, a substantial number of pa-
tients discontinued tacrolimus due to the adverse events, es-
pecially in the early periods of tacrolimus treatment. There-
fore, physicians should pay attention to adverse events, espe-
cially in the early periods. However, the discontinuation of ta-
crolimus could be affected by many factors, such as the 
presence of alternative therapies and health insurance issues. 
Therefore, the rate of discontinuation may vary depending on 
the situation at the clinical site.
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Fig. 3. Prednisolone dose before and after tacrolimus administration. 
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fore tacrolimus administration.
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The limitations of this study are mostly related to its retro-
spective study design and the nature of data collection. Howev-
er, the results of this study represent one of the few published 
works on the use of tacrolimus for MG in a real-life setting. In 
this study, most patients (64%) showed mild weakness or no 
symptoms at the beginning of tacrolimus administration. Ad-
ditionally, information about the clinical status and oral pred-
nisolone dose was obtained from patients who continued 
treatment with tacrolimus. Therefore, this study may not be free 
from selection bias, which would result in inclusion of data 
only from patients with a mild disease course and good prog-
nosis or in whom tacrolimus was effective and led to a posi-
tive result on the steroid-sparing effect of tacrolimus. Further-
more, the patients with MG were on other immune modulating 
therapies and/or had thymectomy performed prior to tacroli-
mus. In the event of acute exacerbation, intensive treatment 
was applied. It should be considered that these treatments 
may have affected the assessment of tacrolimus efficacy in the 
treatment of MG, including reduction of steroid doses. Never-
theless, a substantial number of patients with MG improved 
after tacrolimus treatment and the oral prednisolone dose pre-
scribed to these patients could be reduced. Considering that 
the subjects in this study had a long disease course and were 
resistant to or dependent on prednisolone over an extended 
period, these results suggest that tacrolimus can be an effective 
therapy with steroid-sparing effects for at least some patients 
with MG. Further studies are required to characterize patients 
with MG who have a favorable response to tacrolimus.
In conclusion, we deemed tacrolimus to be a safe and effec-
tive treatment in our real-world population of patients with 
MG. The steroid-sparing effect was demonstrated after long-
term tacrolimus use.
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